These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9071431)

  • 1. Correlation of titer of antibody to principal neutralizing domain of HIVMN strain with disease progression in Japanese hemophiliacs seropositive for HIV type 1.
    Yamanaka T; Fujimura Y; Ishimoto S; Yoshioka A; Konishi M; Narita N; Mimaya J; Meguro T; Nakasone T; Okamoto Y; Yoshizaki H; Yamada K; Honda M
    AIDS Res Hum Retroviruses; 1997 Mar; 13(4):317-26. PubMed ID: 9071431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.
    Sherefa K; Sällberg M; Sönnerborg A
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1551-6. PubMed ID: 7534097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
    Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
    AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
    Haynes BF; Torres JV; Langlois AJ; Bolognesi DP; Gardner MB; Palker TJ; Scearce RM; Jones DM; Moody MA; McDanal C
    J Immunol; 1993 Aug; 151(3):1646-53. PubMed ID: 8335949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [An enzyme-linked immunosorbent assay determining anti-principal neutralizing determinant antibodies using synthetic peptides deduced from cDNA sequences of HIV-1 V3 loop domain].
    Ishimoto S; Fujimura Y; Yamanaka T; Shimoyama T; Nishida S; Matsuoka H; Nishikawa K; Yoshioka A; Narita N; Honda M
    Rinsho Ketsueki; 1995 Mar; 36(3):193-9. PubMed ID: 7540222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pattern of antibody response against the V3 loop in children with vertically acquired immunodeficiency virus type 1 (HIV-1) infection.
    De Rossi A; Zanotto C; Mammano F; Ometto L; Del Mistro A; Chieco-Bianchi L
    AIDS Res Hum Retroviruses; 1993 Mar; 9(3):221-8. PubMed ID: 7682425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High antigenic cross-reactivity of the V3 consensus sequences of HIV-1 gp120.
    Baillou A; Brand D; Denis F; M'Boup S; Chout R; Goudeau A; Barin F
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1209-15. PubMed ID: 7511395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maternofetal transmission of human immunodeficiency virus-1: the role of antibodies to the V3 primary neutralizing domain.
    Rubinstein A; Goldstein H; Calvelli T; Devash Y; Rubinstein R; Soeiro R; Lyman W
    Pediatr Res; 1993 Jan; 33(1 Suppl):S76-8; discussion S78-9. PubMed ID: 8433879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression.
    Zwart G; van der Hoek L; Valk M; Cornelissen MT; Baan E; Dekker J; Koot M; Kuiken CL; Goudsmit J
    Virology; 1994 Jun; 201(2):285-93. PubMed ID: 7514319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular and antibody responses directed against the HIV-1 principal neutralizing domain in HIV-1-infected children.
    Wiseman G; Rubinstein A; Martinez P; Lambert S; Devash Y; Goldstein H
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):839-45. PubMed ID: 1742076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers.
    Rubinstein A; Goldstein H; Pettoello-Mantovani M; Mizrachi Y; Bloom BR; Furer E; Althaus B; Que JU; Hasler T; Cryz SJ
    AIDS; 1995 Mar; 9(3):243-51. PubMed ID: 7755912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
    Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
    J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of antibody reactivity directed against the V3 domain of certain human immunodeficiency virus type 1 variants during disease progression.
    Schreiber M; Wachsmuth C; Müller H; Hagen C; Schmitz H; van Lunzen J
    J Gen Virol; 1996 Oct; 77 ( Pt 10)():2403-14. PubMed ID: 8887471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV type 1 subtype E-infected patients with broadened, dual (B/E) V3 loop serology have increased cross-neutralizing antibodies.
    Polonis VR; De Souza MS; Chanbancherd P; Chantakulkij S; Jugsudee A; Loomis-Price LD; Vancott TC; Garner R; Markowitz LE; Brown AE; Birx DL
    AIDS Res Hum Retroviruses; 2001 Jan; 17(1):69-79. PubMed ID: 11177385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotyping HIV type 1 by antibody binding to the V3 loop: relationship to viral genotype. WHO Network for HIV Isolation and Characterization.
    Cheingsong-Popov R; Lister S; Callow D; Kaleebu P; Beddows S; Weber J
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1379-86. PubMed ID: 7888191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human immunodeficiency virus (HIV) type 1 strain MN neutralizing antibody in HIV-infected children: correlation with clinical status and prognostic value.
    Robert-Guroff M; Roilides E; Muldoon R; Venzon D; Husson R; Marshall D; Gallo RC; Pizzo PA
    J Infect Dis; 1993 Mar; 167(3):538-46. PubMed ID: 7680059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.